01.04.2017 | Letter to the Editor
Association between a cardiovascular disease risk assessment and the molecular response to tyrosine kinase inhibitors in chronic-phase chronic myeloid leukemia patients
Erschienen in: Medical Oncology | Ausgabe 4/2017
Einloggen, um Zugang zu erhalten